Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 13/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198620 | 0.92 | GRIN2B (0.49) | GRIN2BSCN9AMKNK1MKNK2MTOR | |
| SCHEMBL5199183 | 0.84 | SCN9A (0.42) | GRIN2BSCN9AGRIN1 | |
| SCHEMBL5197595 | 0.82 | HPGD (0.47) | GRIN2BSCN9A | |
| SCHEMBL5198412 | 0.82 | HPGD (0.44) | GRIN2BSCN9A | |
| SCHEMBL5196260 | 0.82 | GRIN2B (0.40) | GRIN2BSCN9AMAPT | |
| SCHEMBL5934718 | 0.82 | NR1H4 (0.42) | GRIN2BSCN9AGRIN1 | |
| SCHEMBL5303597 | 0.81 | MTOR (0.39) | SCN9AMTORMAPT | |
| SCHEMBL5198409 | 0.81 | GRIN2B (0.43) | GRIN2BSCN9AMAPT | |
| SCHEMBL5197401 | 0.81 | ALDH1A1 (0.39) | GRIN2BSCN9A | |
| SCHEMBL5197808 | 0.81 | SCN9A (0.38) | GRIN2BSCN9AGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | GRIN2B 1821/4885SCN9A 4015/4885GRIN1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.